2. ARS Pharmaceuticals Inc. (NASDAQ:SPRY)
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) takes the second position among the 10 best stocks under $10 that could triple, with shares recently trading at approximately $7 after falling 6.23%. The biopharmaceutical company is developing and commercializing treatments for severe allergic reactions, led by neffy, an epinephrine nasal spray designed to treat anaphylaxis without the use of a needle.
The central investment thesis for ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is relatively easy to understand. Epinephrine is the established emergency treatment for anaphylaxis, but it has traditionally been administered through an injection. Many patients, parents, caregivers, and children feel anxious or hesitant about needles, which can lead to delays in treatment during a medical emergency.
Neffy attempts to address that problem by delivering epinephrine through a nasal spray. A needle-free treatment could make administration easier, reduce hesitation, and expand the number of people willing and able to carry and use epinephrine promptly.
On July 8, ARS Pharmaceuticals Inc. (NASDAQ: SPRY) announced a significant leadership transition. Effective July 6, company co-founder and Chief Executive Officer Richard Lowenthal was no longer employed by the business. Donn Casale, who had been serving as president, was appointed the new chief executive officer and a member of the company’s board of directors beginning July 7.
Unexpected executive transitions can create uncertainty, particularly when a company is moving from drug development into full commercial execution. Investors may question whether the leadership change reflects strategic disagreements, operational problems, commercial challenges, or a planned shift toward a different type of executive expertise.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) emphasized Casale’s more than 25 years of experience across the biopharmaceutical industry and commercial leadership. His background appears directly relevant to the company’s current needs because neffy’s long-term value will depend not only on regulatory approval but also on payer coverage, physician education, patient awareness, distribution, and sales execution.
Casale previously served as Chief Commercial Officer at Dynavax Technologies, where he played an important role in expanding annual revenue for HEPLISAV-B, a hepatitis B vaccine, to more than $300 million. The vaccine reportedly captured more than half of the U.S. market before Dynavax was acquired by Sanofi for approximately $2.2 billion.
That record gives investors a concrete reason to pay attention to the transition. ARS Pharmaceuticals Inc. (NASDAQ: SPRY) now needs a leader capable of turning a differentiated medical product into a widely used commercial treatment. Casale’s experience scaling a vaccine, competing for market share, working with healthcare providers, and navigating payer systems could be useful as neffy expands.
A strong product does not automatically produce strong sales. Pharmaceutical commercialization requires physicians to understand when and how to prescribe the treatment. Pharmacies must stock or distribute it efficiently. Insurers must decide whether to cover it and under what conditions. Patients must learn that the product exists, believe that it can help them, and obtain it at an affordable price.
The payer-access challenge became visible on June 24, when ARS Pharmaceuticals Inc. (NASDAQ: SPRY) provided an update concerning insurance coverage for neffy. Based on the latest available feedback, the company said no new coverage decisions or commercial formulary additions had been issued for neffy during the July 1 review cycle.
The absence of new formulary decisions may delay broader patient access. Even when a treatment is approved and available, insurance restrictions can limit adoption. Patients may face prior-authorization requirements, higher out-of-pocket costs, step-therapy rules, or other administrative barriers.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) said it would continue working with additional payers to improve coverage. Management also emphasized that neffy remained broadly accessible to commercially insured patients through direct coverage arrangements and a newly introduced retail cash option.
The retail cash option could help patients who are uninsured, underinsured, or unable to secure immediate coverage through their health plans. However, the effectiveness of this strategy will depend on the out-of-pocket price, patient willingness to pay, and whether the company can make the purchasing process simple.
The commercial opportunity is substantial because severe allergies affect both adults and children. Patients at risk of anaphylaxis may include those with food allergies, insect-sting allergies, medication allergies, or other serious immune reactions.
Many patients are advised to carry epinephrine at all times, often in more than one location. A family may require several devices for home, school, work, travel, and other environments. This creates the possibility of recurring demand, although the market is already served by established injectable epinephrine products.
The major advantage of neffy is convenience. A nasal spray may be less intimidating and potentially easier for an untrained person to administer during an emergency. This could be particularly valuable in schools, restaurants, workplaces, aircraft, public venues, and households where a patient may suddenly become unable to treat themselves.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) must nevertheless convince healthcare providers that the nasal spray delivers reliable epinephrine exposure across different patient conditions. Physicians may consider factors such as nasal congestion, allergies, improper technique, product storage, dosing consistency, and the speed of treatment.
The company must also compete with widely recognized epinephrine autoinjector brands. Established products benefit from years of physician familiarity, emergency-treatment protocols, school policies, and insurance coverage. Neffy’s success will depend on whether its convenience is strong enough to change prescribing habits and patient preferences.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) is a biopharmaceutical company focused on developing and commercializing treatments for serious allergic reactions. Neffy allows epinephrine to be administered through the nose rather than through an injection for emergencies such as anaphylaxis.
For investors searching for healthcare stocks under $10, commercial-stage biotech stocks, allergy-treatment stocks, and small-cap pharmaceutical companies with blockbuster potential, ARS Pharmaceuticals Inc. (NASDAQ: SPRY) offers a more commercially advanced opportunity than many clinical-stage names.
The main question is no longer simply whether the treatment can receive regulatory approval. The question is whether management can build widespread coverage, convince physicians to prescribe it, make it affordable for patients, and establish a durable position within the emergency-allergy market.
The new CEO’s commercial track record may improve confidence in that effort. However, payer delays and leadership changes have created additional uncertainty at a critical stage.
ARS Pharmaceuticals Inc. (NASDAQ: SPRY) could become one of the most successful stocks under $10 if neffy develops into a broadly used alternative to injectable epinephrine. The opportunity is large, the product is easy to understand, and the unmet need is real. Execution will now determine whether that promise translates into meaningful revenue growth and long-term shareholder returns.
Click next to see the following stock...
